Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at JMP Securities

Aura Biosciences (NASDAQ:AURA) had its price target hoisted by JMP Securities from $19.00 to $23.00 in a report issued on Friday morning, Benzinga reports. They currently have a market outperform rating on the stock.

AURA has been the topic of several other research reports. Lifesci Capital upgraded shares of Aura Biosciences to a strong-buy rating in a report on Monday, September 9th. HC Wainwright initiated coverage on shares of Aura Biosciences in a research note on Thursday, July 25th. They issued a buy rating and a $21.00 price objective for the company.

Aura Biosciences Stock Performance

Shares of NASDAQ AURA opened at $9.97 on Friday. Aura Biosciences has a 52-week low of $5.99 and a 52-week high of $12.35. The stock has a market cap of $493.94 million, a P/E ratio of -5.36 and a beta of 0.35. The firm has a 50 day moving average price of $8.58 and a two-hundred day moving average price of $7.87.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.04. Analysts predict that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Institutional Trading of Aura Biosciences

Several institutional investors have recently made changes to their positions in AURA. Trexquant Investment LP lifted its holdings in Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after acquiring an additional 6,809 shares during the period. Franklin Resources Inc. bought a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $5,317,000. TBH Global Asset Management LLC lifted its stake in Aura Biosciences by 82.3% in the fourth quarter. TBH Global Asset Management LLC now owns 60,322 shares of the company’s stock valued at $534,000 after purchasing an additional 27,225 shares during the last quarter. Decheng Capital LLC bought a new position in Aura Biosciences during the fourth quarter valued at $4,568,000. Finally, Monashee Investment Management LLC purchased a new stake in Aura Biosciences in the fourth quarter worth $1,758,000. Institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.